I. Design and P. , 19 II-2 Méthode de recueil des informations 19 II-3 Méthode de recueil des critères de jugement, 21 II-7 Analyse statistique, p.22

J. Guéguen and D. Garon, Biodiversité et évolution du monde fongique, EDP Sciences, 2015.

M. Blackwell, The Fungi: 1, 2, 3 ... 5.1 million species?, American Journal of Botany, vol.98, issue.3, pp.426-464, 2011.
DOI : 10.3732/ajb.1000298

D. Hibbett, M. Binder, J. Bischoff, M. Blackwell, P. Cannon et al., A higher-level phylogenetic classification of the Fungi, Mycological Research, vol.111, issue.5, pp.509-556, 2007.
DOI : 10.1016/j.mycres.2007.03.004

C. Kauffman, Fungal Infections, Proceedings of the American Thoracic Society, vol.3, issue.1, pp.35-40, 2006.
DOI : 10.1513/pats.200510-110JH

M. Singer, C. Deutschman, C. Seymour, M. Shankar-hari, D. Annane et al., The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3), JAMA, vol.315, issue.8, pp.801-811, 2016.
DOI : 10.1001/jama.2016.0287

G. Martin, D. Mannino, S. Eaton, and M. Moss, The Epidemiology of Sepsis in the United States from 1979 through 2000, New England Journal of Medicine, vol.348, issue.16, pp.1546-54, 2000.
DOI : 10.1056/NEJMoa022139

D. Bitar, O. Lortholary, L. Strat, Y. Nicolau, J. Coignard et al., Population-based analysis of invasive fungal infections, Emerg Infect Dis. juill, vol.20, issue.7, pp.1149-55, 2001.

T. Horan, M. Andrus, and M. Dudeck, CDC/NHSN surveillance definition of health care???associated infection and criteria for specific types of infections in the acute care setting, American Journal of Infection Control, vol.36, issue.5, pp.309-341, 2008.
DOI : 10.1016/j.ajic.2008.03.002

P. Morlat, C. Roussillon, S. Henard, D. Salmon, F. Bonnet et al., Causes of death among HIV-infected patients in France in 2010 (national survey), ):1181?91. 11 Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey, pp.645-53, 2000.
DOI : 10.1097/QAD.0000000000000222

G. Morace, E. Borghi, and P. Charles, Fungal infections in ICU patients: epidemiology and the role of diagnostics Fungal sepsis in the ICU: are we doing better? Trends in incidence, diagnosis, and outcome, ):950?6. 14. Blot S):1396?405. 15. Shoham S, Marwaha S. Invasive fungal infections in the ICU, pp.78-92, 2010.

J. Vincent, J. Rello, J. Marshall, E. Silva, A. Anzueto et al., International study of the prevalence and outcomes of infection in intensive care units Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study Multistate Point- Prevalence Survey of Health Care?Associated Infections, 665?70. 18. Magill SS):1198?208. 19. Stéphan F al. Molecular diversity and routes of colonization of Candida albicans in a surgical intensive care unit, as studied using microsatellite markers. Clin Infect Dis Off Publ Infect Dis Soc Am. 15 déc, pp.1477-83, 2002.

G. Ramage, S. Saville, D. Thomas, L. Jlcruz, M. López-romero et al., Candida biofilms: an update Candida species: new insights into biofilm formation, 755?71. 22. Pfaller M, Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, pp.2004-2008323, 2005.

S. Ascioglu, J. Rex, B. De-pauw, J. Bennett, J. Bille et al., Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus Epidemiology of Candida species infections in critically ill non-immunosuppressed patients, Clin Infect Dis Off Publ Infect Dis Soc Am. 1 janv Lancet Infect Dis. nov, vol.343, issue.111, pp.685-702, 2002.

O. Leroy, J. Gangneux, P. Montravers, J. Mira, F. Gouin et al., Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: A multicenter, prospective, observational study in France (2005???2006), Critical Care Medicine, vol.37, issue.5, pp.1612-1620, 2005.
DOI : 10.1097/CCM.0b013e31819efac0

URL : https://hal.archives-ouvertes.fr/hal-00676319

N. C. Plantinga, T. Johnson, M. Scott, W. Van-de-vosse, E. et al., Tolllike receptor 1 polymorphisms increase susceptibility to candidemia, J Infect Dis. 15 mars, vol.5205, issue.6, pp.4675-27934, 2012.

O. Lortholary, C. Renaudat, K. Sitbon, Y. Madec, L. Denoeud-ndam et al., Worrisome trends in incidence and mortality of candidemia in intensive care units, 2002.
URL : https://hal.archives-ouvertes.fr/pasteur-01405246

P. Bosshard, Incubation of fungal cultures: how long is long enough? Mycosis Study Group. Longer incubation times for yeast fungemia: importance for presumptive treatment, Mycoses. sept Diagn Microbiol Infect Dis. oct, vol.5480, issue.302, pp.539-545119, 2011.

C. Clancy, M. Nguyen, . J. Lipman, T. Sorrell, A. Kumar et al., Finding the « missing 50% » of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care Prophylaxis, empirical and preemptive treatment of invasive candidiasis Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock, Clin Infect Dis Off Publ Infect Dis Soc Am. mai Curr Opin Crit Care. oct Crit Care Med. juin, vol.561634, issue.956, pp.470-474, 2006.

M. Morrell, V. Fraser, M. Kollef, S. Micek, N. Hampton et al., Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality Septic shock attributed to Candida infection: importance of empiric therapy and source control, 3640?5. 35. Kollef M, pp.1739-1785, 2005.

S. Bailly, L. Bouadma, E. Azoulay, M. Orgeas, C. Adrie et al., Failure of Empirical Systemic Antifungal Therapy in Mechanically Ventilated Critically Ill Patients, American Journal of Respiratory and Critical Care Medicine, vol.191, issue.10, pp.1139-1185, 2015.
DOI : 10.1164/rccm.201409-1701OC

URL : https://hal.archives-ouvertes.fr/hal-01393561

P. Eggimann, P. Francioli, J. Bille, R. Schneider, M. Wu et al., Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata, Crit Care Med. juin J Clin Microbiol. avr, vol.2750, issue.64, pp.1199-203, 1999.

O. Lortholary, M. Desnos-ollivier, K. Sitbon, A. Fontanet, S. Bretagne et al., Recent Exposure to Caspofungin or Fluconazole Influences the Epidemiology of Candidemia: a Prospective Multicenter Study Involving 2,441 Patients, Antimicrobial Agents and Chemotherapy, vol.55, issue.2, pp.532-540, 2011.
DOI : 10.1128/AAC.01128-10

URL : https://hal.archives-ouvertes.fr/hal-00818523

F. Taccone, A. Van-den-abeele, P. Bulpa, B. Misset, W. Meersseman et al., Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes Disponible sur: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344741/ 42 Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes, Crit Care BMC Infect Dis, vol.1913, issue.23, p.29, 2013.

S. Balajee, R. Kano, J. Baddley, S. Moser, K. Marr et al., Molecular Identification of Aspergillus Species Collected for the Transplant-Associated Infection Surveillance Network, Journal of Clinical Microbiology, vol.47, issue.10, pp.3138-3179, 2009.
DOI : 10.1128/JCM.01070-09

B. Segal and . Aspergillosis, Aspergillosis, New England Journal of Medicine, vol.360, issue.18, pp.1870-84, 2009.
DOI : 10.1056/NEJMra0808853

T. Patterson, G. Thompson, D. Denning, J. Fishman, S. Hadley et al., Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America, Clin Infect Dis Off Publ Infect Dis Soc Am. 15 août, vol.63, issue.4, pp.1-60, 2016.

D. Pauw, B. Walsh, T. Donnelly, J. Stevens, D. Edwards et al., Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group Clin Infect Dis Off Publ Infect Dis Soc Am. 15 juin Impact of antifungal prescription on relative distribution and susceptibility of Candida spp. -Trends over 10 years, 103?11. 48. Fournier P al. Antifungal use influences Candida species distribution and susceptibility in the intensive care unit, pp.2880-2886, 2008.

J. Brajtburg, W. Powderly, G. Kobayashi, and G. Medoff, Amphotericin B: current understanding of mechanisms of action):183?8. 50. Laniado-Laborín R, Cabrales-Vargas MN. Amphotericin B: side effects and toxicity, Antimicrob Agents Chemother. févr Rev Iberoam Micol. 31 déc, vol.3426, issue.24, pp.223-230, 1990.

J. Wingard, M. White, E. Anaissie, J. Raffalli, J. Goodman et al., A Randomized, Double-Blind Comparative Trial Evaluating the Safety of Liposomal Amphotericin B versus Amphotericin B Lipid Complex in the Empirical Treatment of Febrile Neutropenia, Clinical Infectious Diseases, vol.31, issue.5, pp.1155-63, 2000.
DOI : 10.1086/317451

D. Kuhn, T. George, J. Chandra, P. Mukherjee, and M. Ghannoum, Antifungal Susceptibility of Candida Biofilms: Unique Efficacy of Amphotericin B Lipid Formulations and Echinocandins, Antimicrobial Agents and Chemotherapy, vol.46, issue.6
DOI : 10.1128/AAC.46.6.1773-1780.2002

D. Dreyfuss, R. J. Gaudry, and S. , Amphotericin B Deoxycholate for Candidiasis in Intensive Care Unit Patients Revisited: Medical, Ethical, and Financial Implications, American Journal of Respiratory and Critical Care Medicine, vol.187, issue.6, pp.1773-80, 2002.
DOI : 10.1164/ajrccm.187.6.661

U. Eriksson, B. Seifert, and A. Schaffner, Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance, 579?82. 55. Ghannoum MA, Rice LB, pp.501-518, 1999.

N. V. Greer, P. Balding, C. Porro, K. Mclean, M. Sutcliffe et al., How do azoles inhibit cytochrome P450 enzymes? A density functional study Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes, 201?11. 59. Lat A, Thompson GR. Update on the optimal use of voriconazole for invasive fungal infections. Infect Drug Resist. 3 févr, pp.241-249, 2003.

S. Chen, M. Slavin, and T. Sorrell, Echinocandin Antifungal Drugs in Fungal Infections, Drugs, vol.31, issue.7, pp.11-41, 2011.
DOI : 10.1177/0091270006296764

P. Uppuluri, A. Srinivasan, A. Ramasubramanian, and J. Lopez-ribot, Effects of Fluconazole, Amphotericin B, and Caspofungin on Candida albicans Biofilms under Conditions of Flow and on Biofilm Dispersion, 3591?3. 62. Sucher AJ, Chahine EB, Balcer HE. Echinocandins: the newest class of antifungals, pp.1647-57, 2009.
DOI : 10.1128/AAC.01701-10

E. Ashley, R. Lewis, J. Lewis, C. Martin, D. Andes et al., Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America, ):S28?39. 64, pp.1-50, 2006.

G. Guyatt, A. Oxman, G. Vist, R. Kunz, Y. Falck-ytter et al., GRADE: an emerging consensus on rating quality of evidence and strength of recommendations ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients, 924?6. 66):96?128. 68. Prise en charge des candidoses et aspergilloses invasives de l'adulte [Internet]. SFAR -Société Française d'Anesthésie et de Réanimation, p.2015, 2008.

P. Muñoz, M. Valerio, A. Vena, and E. Bouza, Antifungal stewardship in daily practice and health economic implications, Mycoses, vol.52, issue.Suppl. 3, pp.14-25, 2015.
DOI : 10.1093/mmy/myt025

J. Jones, D. Hunter, H. Abdoul, M. Loustau, O. Sibony et al., Consensus methods for medical and health services research Using and Reporting the Delphi Method for Selecting Healthcare Quality Indicators: A Systematic Review, BMJ. 5 août PLOS ONE. 9 juin, vol.3116, issue.70016, p.20476, 1995.

F. Hasson, S. Keeney, and H. Mckenna, Research guidelines for the Delphi survey technique, J Adv Nurs. oct, vol.32, issue.4, pp.1008-1023, 2000.

D. Andes, N. Safdar, J. Baddley, G. Playford, A. Reboli et al., Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials, Clinical Infectious Diseases, vol.54, issue.8, pp.1110-1132, 2012.
DOI : 10.1093/cid/cis021

E. Anaissie and M. Nucci, Far-reaching Conclusions Based on Weak and Missing Data, Clinical Infectious Diseases, vol.55, issue.6, pp.890-893, 2012.
DOI : 10.1093/cid/cis521

J. Cisneros, O. Neth, and J. Pachón, Selection Bias in Andes et al, Clinical Infectious Diseases, vol.55, issue.6, pp.893-894, 2012.
DOI : 10.1093/cid/cis524

A. Reboli, C. Rotstein, P. Pappas, S. Chapman, D. Kett et al., Anidulafungin versus fluconazole for invasive candidiasis Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis, N Engl J Med. 14 juin Crit Care Lond Engl, vol.35615, issue.775, p.253, 2007.

D. Rosa, F. Motta, I. Corcione, S. Cattel, F. et al., Anidulafungin versus fluconazole: clinical focus on IDSA and ESCMID guidelines, Infez Med Riv Period Eziologia Epidemiol Diagn Clin E Ter Delle Patol Infett. juin, vol.22, issue.2, pp.107-118, 2014.

O. Leroy, S. Bailly, J. Gangneux, M. J. Devos, P. Dupont et al., Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study, Ann Intensive Care. déc, vol.6, issue.12, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01259216

M. Arendrup, S. Sulim, A. Holm, L. Nielsen, S. Nielsen et al., Diagnostic Issues, Clinical Characteristics, and Outcomes for Patients with Fungemia? Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of AmericaAntifungal treatment for suspected or proved candidiasis in the critically ill], ):3300?8. 81503?35. 82. Massanet P, pp.232-241, 2009.

E. Azoulay, H. Dupont, A. Tabah, O. Lortholary, J. Stahl et al., Systemic antifungal therapy in critically ill patients without invasive fungal infection*, Critical Care Medicine, vol.40, issue.3, pp.813-835, 2012.
DOI : 10.1097/CCM.0b013e318236f297

J. Timsit, E. Azoulay, C. Schwebel, P. Charles, M. Cornet et al., Colonization, and Multiple Organ Failure, JAMA, vol.316, issue.15
DOI : 10.1001/jama.2016.14655

URL : https://hal.archives-ouvertes.fr/hal-01405822

C. Bretonnière, K. Lakhal, T. Lepoivre, D. Boutoille, and F. Morio, What is the role of empirical treatment for suspected invasive candidiasis in non-neutropenic non transplanted patients in the intensive care unit????Empiricus strikes back!, Journal of Thoracic Disease, vol.8, issue.12, pp.1719-1741, 2016.
DOI : 10.21037/jtd.2016.12.99

M. Arendrup, E. Dzajic, R. Jensen, H. Johansen, P. Kjaeldgaard et al., Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme, Clinical Microbiology and Infection, vol.19, issue.8, pp.343-353, 2013.
DOI : 10.1111/1469-0691.12212

D. Perlin, Echinocandin Resistance in Candida, Clinical Infectious Diseases, vol.61, issue.suppl_6
DOI : 10.1093/cid/civ791

E. Dannaoui, M. Desnos-ollivier, D. Garcia-hermoso, F. Grenouillet, S. Cassaing et al., Candida spp. with Acquired Echinocandin Resistance, France Antifungal deescalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data, Emerg Infect Dis. janv Intensive Care Med. nov, vol.1841, issue.111, 2004.
URL : https://hal.archives-ouvertes.fr/hal-00759177

L. Gall, J. Lemeshow, S. Saulnier, and F. , A New Simplified Acute Physiology Score (SAPS II) Based on a European/North American Multicenter Study, JAMA: The Journal of the American Medical Association, vol.270, issue.24, pp.2957-63, 1993.
DOI : 10.1001/jama.1993.03510240069035

C. León, S. Ruiz-santana, P. Saavedra, B. Almirante, J. Nolla-salas et al., A bedside scoring system (« Candida score ») for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization Candida spp. colonization significance in critically ill medical patients: a prospective study Secondarily documented invasive candidiasis is unpredictable using traditional risk factors in non transplant -non-neutropenic adult ICU patients Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study al. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain, 730?7. 931930?45. 96. Puig-Asensio M, pp.245-254, 2005.

J. Fernandez, B. Erstad, W. Petty, D. Nix, B. Fiori et al., Time to positive culture and identification for Candida blood stream infections Risk Factors and Outcomes of Candidemia Caused by Biofilm-Forming Isolates in a Tertiary Care Hospital Disponible sur, 402?7. 98. Tumbarello M, p.99, 2009.

B. Graham, G. Regehr, and J. Wright, Delphi as a method to establish consensus for diagnostic criteria, Journal of Clinical Epidemiology, vol.56, issue.12, pp.1150-1156, 2003.
DOI : 10.1016/S0895-4356(03)00211-7

J. Pill, The Delphi method: Substance, context, a critique and an annotated bibliography, Socio-Economic Planning Sciences, vol.5, issue.1
DOI : 10.1016/0038-0121(71)90041-3

M. De-villiers, P. De-villiers, and A. Kent, The Delphi technique in health sciences education research, Medical Teacher, vol.18, issue.7, pp.639-682, 2005.
DOI : 10.1353/rhe.1995.0008